secwatch.observer — SEC 8-K summary
======================================

Issuer:     EXAGEN INC. (XGN)
CIK:        0001274737
Form:       8-K
Filed at:   2022-11-14T23:59:59+00:00
Accession:  0001274737-22-000070
Event type: earnings
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 4.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Exagen restates Q2 2022 financials for revenue errors; Q3 revenue $14.7M, guidance raised
--------------------------------------------------------------------------------

- Audit Committee determined revenue recognition errors: revenue overstated $1.4M, AR overstated $0.9M, liabilities understated $0.5M for Q2 2022.
- Q3 2022 revenue $14.7M (vs $12.3M in Q3 2021); net loss $8.1M (vs $7.2M loss).
- Full-year 2022 revenue guidance raised to $40-43M from prior range; Medicare resumed AVISE Lupus payments dating to Q2.
- John Aballi appointed President and CEO, effective with Q3 earnings release.
- Company expects to report at least one material weakness in internal controls over financial reporting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1274737/000127473722000070/0001274737-22-000070-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1274737/000127473722000070/exdx-20221114.htm
  HTML page:      https://secwatch.observer/filing/0001274737-22-000070

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer